Login
Companies $RGEN
$162.78 -$5.01 (2.99%) Live
REPLIGEN CORP logo

REPLIGEN CORP

repligen.com

What Do They Do?

Sells filtration, chromatography and process-measurement systems and consumables for biological drug manufacturing to biopharmaceutical companies, contract manufacturers and other life-sciences companies.

How Do They Make Money?

Biopharmaceutical and life-sciences customers buy bioprocessing products, equipment and related consumables; product sales are generally counted when the products are delivered to customers.

revenue
SegmentShareRevenue
Product Revenue
Sold outright

100%
FY2022: 100%
Royalty and other revenue
<0.1%
FY2022: <0.1%

Who Are Their Customers?

Biopharmaceutical companies and contract manufacturers, along with other life-sciences customers, use its products in biological drug production; diagnostics companies and laboratory researchers are also customers.

Do Revenues Turn Into Profits?

Yes. It kept 7 cents of every revenue dollar as net income in FY2025 and turned 13 cents into free cash flow.

Operating income, FY2025
7% of revenue
▲ Turned profitable vs FY2024 (−$35.1M, −6%)
Net income, FY2025
7% of revenue
▲ Turned profitable vs FY2024 (−$25.5M, −4%)
Free cash flow, FY2025
13% of revenue
▼ −37% vs FY2024 ($149.7M, 24%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +11%
vs $188.8M in Q3 FY2025
Net income
▼ Turned to a loss
vs $14.9M in Q3 FY2025
Product share of revenue vs 100.0% in Q3 FY2025
  • Sep 3, 2026 BioLife merger clears antitrust waiting period The acquisition still awaited BioLife stockholder approval and other customary closing conditions.
  • Jul 28, 2026 Repligen raised full-year guidance It raised organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09.
  • Jul 22, 2026 Repligen agreed to acquire BioLife Solutions BioLife holders are to receive $11.25 cash and 0.1442 Repligen shares per share; closing is subject to customary conditions.

Integrated customer offerings The latest report describes a move from selling individual products toward offering a broader portfolio as integrated solutions across manufacturing steps; the older report describes its product franchises and products.

Broader process analytics The older report lists process analytics as a franchise; the latest adds upstream process-monitoring devices to that offering through an acquired portfolio.

Revenue over time
Product Revenue Royalty and other revenue
$1B$500M$0

Who Do They Compete With?

Competes with Danaher, Thermo Fisher Scientific, MilliporeSigma, and Sartorius

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support